Morgans Research maintain an add recommendation on GI Dynamics (GID) with a price target of $1.61

Morgans Research maintain an add recommendation on GI Dynamics (GID) with a price target of $1.61. Momentum is set to continue and Morgans view 2013 as a strong base-building year, with solid EndoBarrier sales growth underpinned by 50 centres of excellence (COE). Morgans believe momentum can continue, as awareness/adoption grows, 20 additional COEs come online, self-pay markets begin to bear fruit and continued building-blocks are laid for national reimbursement. The Broker increased FY14 net loss by 4% on more reasonable EndoBarrier sales expectations and ongoing infrastructure building, they are encouraged by the growing traction among physicians/ patients and continue to forecast 2016 profitability.


2 topics

The Livewire Equities feed brings you a range of insights that relate to Australian equities

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.